CytoMed Therapeutics Limited GDTC
0.96
0.05
5.49%
as of 25 Sep
- Market cap
- $10.8M
- P/E
- 0.0×
Follow GDTC
Insider Buys
alert about insiders buying in the last 12 month
| Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|
P/E ratio |
— | — | — | — | 0.00 | 0.00 |
P/S ratio |
— | — | — | — | 0.00 | 0.00 |
P/FCF ratio |
— | — | — | — | 0.00 | 0.00 |
P/Operating CF |
— | — | — | — | (4,651.77) | (1,265.17) |
P/B ratio |
— | — | — | — | 1,394.17 | 682.30 |
Price to Tangible BV |
— | — | — | — | 1,408.66 | 694.96 |
EV/Sales |
— | — | — | — | 0.00 | 0.00 |
EV/EBITDA |
— | — | — | — | 0.00 | 0.00 |
EV/Operating CF |
— | — | — | — | (1,328.79) | (521.73) |
EV/FCF |
— | — | — | — | (1,091.57) | (395.63) |
Quick Ratio |
0.44 | 0.86 | 0.60 | 14.08 | 9.89 | 5.17 |
Current Ratio |
0.54 | 1.12 | 0.60 | 14.08 | 9.89 | 5.17 |
Net Debt/EBITDA |
(1.69) | (0.42) | (1.26) | 5.88 | 3.82 | 0.86 |
Debt/Assets |
78.12% | 53.58% | 80.57% | 3.57% | 4.52% | 5.80% |
Debt/Equity |
6.26 | 1.26 | 7.18 | 0.04 | 0.05 | 0.07 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.01 | 0.04 |
Operating CF/Net income |
0.49 | 0.89 | 0.45 | 0.83 | 1.08 | 0.93 |
Capex/Depreciation |
0.00 | 0.00 | (1.20) | (0.15) | (4.46) | (1.75) |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 0.00% | (133.76%) | (197.96%) | (69.92%) | (24.33%) | (51.81%) | |
| 0.00% | (41.27%) | (55.54%) | (47.20%) | (22.00%) | (45.59%) | |
ROIC |
0.00% | 0.00% | (48.09%) | (42.67%) | (20.94%) | (27.51%) |
Return on Tangible Assets |
(177.50%) | (72.44%) | (389.66%) | (36.11%) | (29.10%) | (59.90%) |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | 5,408.31 | 1,763.52 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 2,745.97% | 683.51% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | — | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.00 | 0.00 | 0.01 | 0.02 |
Share Based Compensation of Revenue |
— | — | — | — | 0.00% | 213.99% |
Graham Net Nets |
— | — | — | — | 0.00 | 0.00 |
Graham Number |
— | — | — | — | 0.00 | 0.00 |
Earnings Yield |
— | — | — | — | (8.24%) | (20.90%) |
Free Cash Flow Yield |
— | — | — | — | (0.09%) | (0.25%) |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 |
Operating CF per Share |
0.00 | 0.00 | (0.13) | (0.24) | (0.17) | (0.25) |
Capex per Share |
0.00 | 0.00 | (0.04) | 0.00 | (0.09) | (0.05) |
Free Cash Flow per Share |
0.00 | 0.00 | (0.18) | (0.25) | (0.27) | (0.29) |
Cash per Share |
0.00 | 0.00 | 0.15 | 0.64 | 0.32 | 0.14 |
Shareholders Equity per Share |
0.00 | 0.00 | 0.06 | 0.80 | 0.57 | 0.46 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.00 | 0.00 | 0.06 | 0.80 | 0.57 | 0.46 |
Free Cash Flow |
(0.69) | (1.36) | (1.40) | (2.65) | (3.08) | (3.42) |
Working Capital |
(0.95) | 0.26 | (1.25) | 7.11 | 3.95 | 2.30 |
Capital Expenditures |
(0.19) | (0.43) | (0.35) | (0.04) | (1.09) | (0.55) |
Net Current Asset Value |
(1.42) | (0.16) | (1.60) | 6.80 | 3.64 | 1.97 |
EV/EBIT |
— | — | — | — | 0.00 | 0.00 |
Capex to Sales |
— | — | 0.00 | 0.00 | 21.49 | 2.17 |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | (3,619.06%) | (1,226.91%) |
Price to Operating Income |
— | — | — | — | 0.00 | 0.00 |
| Other line items | ||||||
Depreciation/Fixed assets |
0.12 | 0.13 | 0.16 | 0.18 | 0.10 | 0.11 |
Cash ROIC |
(74.07%) | (51.80%) | (60.73%) | (26.58%) | (41.21%) | (78.50%) |
Accounts Receivable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.06 | 0.26 |
Accounts Payable Turnover |
0.00 | 3.10 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
83.11 | 166.26 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | — | — | — |
Average Receivables |
— | 0.12 | 0.35 | 0.76 | 0.79 | 0.99 |
Average Payables |
— | 0.02 | 0.17 | 0.35 | 0.36 | 0.33 |
Average Assets |
— | 3.70 | 4.21 | 6.64 | 8.37 | 6.79 |
Average Common Equity |
— | 1.14 | 1.18 | 4.48 | 7.57 | 5.97 |
Columns are period end dates